Inflammatory bowel disease and endothelin-1: A review

Critical Care Nursing Quarterly

Volumn 28, Issue 2, 2005, Pages 208-213

  Angerio, Allan D ^a   Bufalino, Dominick ^a   Bresnick, Melissa ^a   Bell, Christine ^a   Brill, Sarah ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Crohn's; Endothelin antagonists; Endothelin 1; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT;

CHRONIC INFLAMMATION; CROHN DISEASE; ENTERITIS; NONHUMAN; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS;

EID: 17444397452     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200504000-00013     Document Type: Review

References (58)

1. Kanazawa S, Tsundoa T, Onuma E, et al. VEGt, BASIC-FGF, and TGF-B in Crohn's disease and ulcerative colitis: a novel mechanism of chronic inflammation. Am J Gastroenterol. 2001;96:822-828.
2. Lashner BA. Epidemiology of inflammatory bowel disease. Gastroenterol Clin N Am. 1995;24:467-474.
3. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin N Am. 1995;24:475-507.
4. Kleer CG, Appelman HD. Surgical pathology of Crohn's disease. Surg Clin N Am. 2001;81:3-30.
5. Aufses AH Jr. The history of Crohn's disease. Surg Clin N Am. 2001;81:1-11.
6. Delaney CP, Fazio VW. Crohn's disease of the small bowel. Surg Clin N Am. 2001;81:137-158.
7. Andres PG, Friedman LS, Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin N Am. 1999;28:255-281.
8. Carucci LR, Levine MS. Radiographic imaging of inflammatory bowel disease. Gastroenterol Clin N Am. 2002;31:93-117.
9. Lee SD, Cohen RD. Endoscopy in inflammatory bowel disease. Gastroenterol Clin N Am. 2002;31: 119-132.
10. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produce by vascular endothelial cells. Nature. 1989;322:411-415.
11. Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol Sci. 1989;10:374-378.
12. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separated genes. Proc Natl Acad Sci U S A. 1989;86:2863-2867.
13. Maggi CA, Giuliani S, Patacchini R, et al. The activity of peptides of the endothelin family in various smooth muscle preparation. Eur J Pharmacol. 1989;174:23-31.
14. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732-735.
15. Lin HY, Kaji EH, Winkle GK, et al. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci U S A. 1991;88:3185-3189.
16. Takayanagi R, Ohnaka K, Takasaki C, et al. Multiple subtypes of endothelin receptors in porcine tissues: characterization by ligand binding, affinity labeling and regional distribution. Regul Pept. 1991;32:23-27.
17. Kitsukawa Y, Gu Z-F, Hildebrand P, et al. Gastric smooth muscle cells possess two classes of endothelin receptors but only one alters contraction. Am J Physiol. 1994;266:G713-G721.
18. B receptor on guinea pig small intestinal smooth muscle cells. Am J Physiol. 1992;25:G308-G311.
19. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor Y in ulcerative colitis. Gastroenterology. 2003;124:1265-1276.
20. Takahashi K, Jones PM, Kanse SM, et al. Endothelin in the gastrointestinal tract. Presence of endothelinlike immunoreactivity, endothelin-1 messenger RNA, endothelin receptors, and pharmacological effect. Gastroenterology. 1990;99:1660-1607.
21. Thomson AB, Keelan M, Thiesen A, et al. Small bowel review: diseases of the small intestine. Dig Dis Sci. 2001;46:2555-2556.
22. Inagaki H, Bishop AE, Escing C, et al. Localization of endothelin-like immunoreactivity and endothelin binding sites in human colon. Gastoenterology. 1991;101:47-54.
23. Williams DL Jr, Jones KL, Colton CD, et al. Identification of high affinity endothelin-1 receptor subtypes in human tissues. Biochem Biophys Res Commun. 1991;180:475-480.
24. Barajas-Lopez L, Huizinga JD. Different mechanisms of contraction generation in circular muscle of canine colon. Am J Physiol. 1989;4:G579-G580.
25. Rakugi H, Tabuchi Y, Nakamaru M, et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun. 1990;169:973-977.
26. Pittet J-F, Morel DR, Hemsen A, et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg. 1991;213:26l-264.
27. Wilson MA, Steeb GD, Garrison RN. Endothelins mediate hypoperfusion during bacteremia. J Surg Res. 1993;55:168-175.
28. Yoshio T, Masuyama J-I, Kohda N, et al. Association of Interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol. 1997;24:489-495.
29. Boros M, Massberg S, Baranyi L, et al. Endothelin 1 induces leukocyte adhesion in submucosal venules of the rat small intestine. Gastroenterology. 1998;114:103-114.
30. Elfernik JG, deKoster BM. Endothelin-induced activation of neutrophil migration. Biochem Pharmacol. 1994;48:865-871.
31. Sanz MJ, Johnston B, Issekutz A, et al. Endothelin-1 causes P-selectin-dependent leukocyte rolling and adhesion within rat mesenteric microvessels. Am J Physiol. 1999;277:H1823-1830.
32. Cui P, Tani K, Kitamura H, et al. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J Leukoc Biol. 2001;70:306-312.
33. Thornton M, Solomon MJ. Crohn's disease: in defense of a microvascular aetiology. Int J Colorectal Dis. 2002;17:287-297.
34. A receptors. Clin Sci. 2002;103:31S-34S.
35. Szalay L, Kaszaki J, Nagy S, et al. Endothelin-1 induces mucosal mast cell degranulation in the rat small intestine. Life Sci. 2000;67:1947-1958.
36. Kanwar S, Kubes P. Mast cells contribute to ischemia-reperfusion-induced granulocyte infiltration and intestinal dysfunction. Am J Physiol. 1994;267:G316-G321.
37. Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999;104:517-523.
38. Braegger CP, MacDonald TT. Immune mechanisms in chronic inflammatory bowel disease. Ann Allergy. 1994;72:135-141.
39. Yoshio T, Masuyama J, Mimori, et al. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis. 1995;54:361-365.
40. Yamamoto T, Takahashi Y, Kuno S, et al. Effects of anti-endothelial cell antibody in pre-eclampsia on endothelin-1 release from cultured endothelial cells. Immunol Cell Biol. 1997;75:340-344.
41. Angerio AD. Endothelin-mediated preeclampsia at high altitude. Crit Care Nurs Q. 2000;23(2):73-78.
42. Murch SH, Braegger CP, Sessa WC, et al. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet. 1992;339:381-385.
43. Angerio AD, Fink DA. New strategies in the prevention of restenosis. Crit Care Nurs Q. 2001;24:62-68.
44. Kahaleh MB, Fan PS. Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol. 1997;15:163-167.
45. Browatzki M, Schmidt J, Kubler W, et al. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol. 2000;95:98-105.
46. Verma S, Li SH, Badiwala MV, et al. Endothelin anatagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;23:1890-1896.
47. Willemsen LE, Schreurs CC, Kroes H, et al. A coculture model mimicking the intestinal mucosa reveals a regulatory role for myofibroblasts in immune-mediated barrier disruption. Dig Dis Sci. 2002;47:2316-2324.
48. Shimada M, Andoh A, Hata K, et al. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol. 2002;168:861-868.
49. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts, I: paracrine cells important in health and disease. Am J Physiol. 1999;277:C1-C9.
50. Badid C, Vincent M, Fouque D, et al. Myofibroblast: a prognostic marker and target cell in progressive renal disease. Ren Fail. 2001;23:543-549.
51. Kernochan LE, Tran BN, Tangkijvanich P, et al. Endothelin-1 stimulates human colonic myofibroblast contraction and migration. Gut. 2002;50:65-70.
52. Stein RD, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin N Am. 1999;28:297-321.
53. Sands BE. Novel therapies for inflammatory bowel disease. Gastroenterol Clin N Am. 1999;28:323-351.
54. Gilbert RE, Rumble JR, Cao Z, et al. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res. 2000;86:158-165.
55. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Eng J Med. 2002;346:896-903.
56. Hogaboam CM, Muller MJ, Collins SM, et al. An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis. Eur J Pharmacol. 1996;309:261-269.
57. Padol I, Huang JQ, Hogaboam CM, et al. Therapeutic effects of the endothelin receptor antagonist Ro48-5695 in the TNS/DNBS rat model of colitis. Eur J Gastroenterol Hepatol. 2000;12:257-265.
58. McCartney SA, Ballinger AB, Vojnovic I, et al. Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzene sulphonic acid-induced colitis. Life Sci. 2002;71:1893-1904.